What's in the PD Clinical Trial Pipeline?

What's in the PD Clinical Trial Pipeline?

pdf.org/en/pipeline

Pipeline Trends: Neuroprotective Compounds

Several of the potentially neuroprotective compounds in the PD pipeline focus on alpha-synuclein, the protein that forms toxic clumps in the brain cells of people with PD. Potential therapies would harness the immune system to clear alpha-synuclein or use vaccines to prevent or halt alpha-synuclein build-up. In addition, a few others — for example, isradipine — have been used for years to treat other health conditions and supplements such as NAC and inosine.

Does anyone have experience with any of these Phase I / II trials?

Phase I:

AAV2-GDNF. A gene therapy treatment designed to boost levels of GDNF, a naturally occurring protein that may protect dopamine neurons in the brain.

BIIB054. An immunotherapy that clears alpha-synuclein, a protein whose build-up is thought to contribute to PD.

NPT200-11. A drug designed to stabilize the brain protein alpha-synuclein, whose misfolding is related to PD.

PRX002. An immunotherapy that clears alpha-synuclein, a protein whose build-up is thought to contribute to PD.

1 Reply

oldestnewest

You may also like...